Holen Sie sich die Stockscreener-App
36.90
0.65%
0.24
Handel nachbörslich:
36.30
-0.60
-1.63%
Schlusskurs vom Vortag:
$36.66
Offen:
$36.75
24-Stunden-Volumen:
3.53M
Relative Volume:
1.00
Marktkapitalisierung:
$15.95B
Einnahmen:
$2.31B
Nettoeinkommen (Verlust:
$1.66B
KGV:
16.04
EPS:
2.3
Netto-Cashflow:
$827.02M
1W Leistung:
+3.59%
1M Leistung:
-2.59%
6M Leistung:
+10.74%
1J Leistung:
+26.07%
1-Tages-Spanne:
$36.39
$36.96
1-Wochen-Bereich:
$35.52
$36.96
52-Wochen-Spanne:
$24.05
$38.00
Royalty Pharma Plc Stock (RPRX) Company Profile
Firmenname
Royalty Pharma Plc
Sektor
Branche
Telefon
(212) 883-0200
Adresse
110 EAST 59TH STREET, NEW YORK, NY
Vergleichen Sie RPRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
36.90 | 15.64B | 2.31B | 1.66B | 827.02M | 2.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-16 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-06-03 | Herabstufung | UBS | Buy → Neutral |
| 2022-06-14 | Fortgesetzt | UBS | Buy |
| 2022-05-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-04-27 | Eingeleitet | Goldman | Buy |
| 2022-04-14 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-10-29 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-07-30 | Eingeleitet | Tigress Financial | Buy |
| 2020-11-09 | Hochstufung | UBS | Neutral → Buy |
| 2020-07-14 | Eingeleitet | Evercore ISI | In-line |
| 2020-07-13 | Eingeleitet | BofA Securities | Buy |
| 2020-07-13 | Eingeleitet | Citigroup | Neutral |
| 2020-07-13 | Eingeleitet | Cowen | Outperform |
| 2020-07-13 | Eingeleitet | Goldman | Neutral |
| 2020-07-13 | Eingeleitet | JP Morgan | Neutral |
| 2020-07-13 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-07-13 | Eingeleitet | SunTrust | Buy |
| 2020-07-13 | Eingeleitet | UBS | Neutral |
Alle ansehen
Royalty Pharma Plc Aktie (RPRX) Neueste Nachrichten
Royalty Pharma (NASDAQ:RPRX) Rating Increased to Buy at Wall Street Zen - MarketBeat
Magnetar Financial LLC Makes New Investment in Royalty Pharma PLC $RPRX - MarketBeat
Compound Planning Inc. Acquires New Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Is Royalty Pharma plc stock forming a cup and handleJuly 2025 Action & Free High Accuracy Swing Entry Alerts - khodrobank.com
Is Royalty Pharma plc still worth holding after the dipQuarterly Performance Summary & Accurate Technical Buy Alerts - Newser
How to monitor Royalty Pharma plc with trend dashboardsQuarterly Earnings Report & Expert Curated Trade Ideas - Newser
Combining machine learning predictions for Royalty Pharma plcShort Setup & Capital Efficiency Focused Strategies - Newser
Royalty Pharma PLC $RPRX Shares Sold by BNP Paribas Financial Markets - MarketBeat
Royalty Pharma PLC $RPRX Shares Sold by Canada Pension Plan Investment Board - MarketBeat
Applying sector rotation models to Royalty Pharma plcRecession Risk & Long-Term Capital Growth Strategies - Newser
Will Royalty Pharma plc benefit from AI trends2025 Volatility Report & Capital Protection Trading Alerts - khodrobank.com
Royalty Pharma prices $2 billion senior unsecured notes offering - StreetInsider
Ieq Capital LLC Acquires 27,597 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Is a relief rally coming for Royalty Pharma plc holders2025 Market WrapUp & Safe Entry Point Identification - Newser
Royalty Pharma Prices $2 Billion Debt Offering - MarketScreener
Zenas BioPharma secures $300M funding from Royalty Pharma for obexelimab royalties. - AInvest
Royalty Pharma plc Announces Pricing of $2.0 Billion of Senior Unsecured Notes - MarketScreener
Is Royalty Pharma plc forming a reversal patternMarket Risk Summary & Weekly High Potential Stock Alerts - Newser
Technical signs of recovery in Royalty Pharma plc2025 Big Picture & Free Safe Capital Growth Stock Tips - Newser
How to interpret RSI for Royalty Pharma plc stockJuly 2025 Review & Fast Gaining Stock Reports - Newser
Royalty Pharma prices $2B senior unsecured notes - MSN
Applying Wyckoff theory to Royalty Pharma plc stockGlobal Markets & Real-Time Buy Zone Alerts - Newser
Will breakout in Royalty Pharma plc lead to full recovery2025 Analyst Calls & Fast Entry High Yield Stock Tips - Newser
Can Royalty Pharma plc expand its profit marginsJuly 2025 Final Week & Safe Capital Growth Trade Ideas - khodrobank.com
Royalty Pharma plc recovery potential after sell offEarnings Recap Report & Fast Gain Stock Trading Tips - Newser
Royalty Pharma Prices $2 Bln Offering Of Senior Unsecured Notes - Nasdaq
Royalty Pharma Announces Pricing of $2.0 Billion of Senior Unsecured Notes - The Manila Times
$2 Billion Debt Offering: Royalty Pharma Secures Major Financing Across Three Long-Term Tranches - Stock Titan
Royalty Pharma says it announces pricing of $2.0 billion of senior unsecured notes - MarketScreener
Royalty Pharma Announces Pricing of $2.0 Billion of Senior Unsecured Notes - GlobeNewswire Inc.
Using data filters to optimize entry into Royalty Pharma plcQuarterly Portfolio Report & Verified High Yield Trade Plans - Newser
Wuxi XDC offers up to 22.3 million shares at HK$58.85 each - AInvest
Using data tools to time your Royalty Pharma plc exit2025 Price Targets & Free Long-Term Investment Growth Plans - Newser
Full technical analysis of Royalty Pharma plc stockWeekly Risk Summary & Precise Trade Entry Recommendations - Newser
What are the analyst revisions for GCLWWIs Royalty Pharma plc stock a good investment in YEARJuly 2025 PostEarnings & Risk Managed Trade Strategies - خودرو بانک
Zenas Biopharma and Royalty Pharma enter into obexelimab funding agreement for up to $300 million - MarketScreener
Zenas BioPharma, Royalty Pharma Enter $300 Million Funding Agreement for Obexelimab - MarketScreener
Zenas BioPharma Secures Up To $300 Mln Funding From Royalty Pharma For Obexelimab - Nasdaq
Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million - citybiz
Royalty Pharma and Zenas BioPharma Enter Into Obexelimab Funding Agreement for Up to $300 Million - GlobeNewswire
Royalty Pharma provides up to $300 million to Zenas BioPharma for obexelimab - StreetInsider
$300M Biotech Deal: Royalty Pharma Backs Promising Autoimmune Drug with Blockbuster Potential - Stock Titan
OMERS ADMINISTRATION Corp Boosts Stock Position in Royalty Pharma PLC $RPRX - MarketBeat
Zenas BioPharma, Inc. and Royalty Pharma Enter into Obexelimab Funding Agreement for Up to $300 Million - MarketScreener
Caisse DE Depot ET Placement DU Quebec Raises Stock Position in Royalty Pharma PLC $RPRX - MarketBeat
American Century Companies Inc. Raises Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Is Royalty Pharma plc a defensive stock2025 Trading Volume Trends & Fast Moving Stock Trade Plans - khodrobank.com
Royalty Pharma to buy royalty interest in Amgen Imdelltra for up to USD 950 million - Medical Dialogues
GIMV: portfolio return of 4.7% for 10 of current fiscal year - AInvest
Is Royalty Pharma plc stock forming a triangle pattern2025 Earnings Impact & Fast Moving Market Watchlists - khodrobank.com
Fed Watch: What is the long term forecast for Royalty Pharma plc stockMarket Growth Report & Capital Efficient Trade Techniques - khodrobank.com
Finanzdaten der Royalty Pharma Plc-Aktie (RPRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.75%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):